ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 246 entries already.
Safeguarding temperature-sensitive materials is critical, and Ultra-Low Freezers (ULTs) ensure sample integrity at very low temperatures. Today’s customers demand not just reliability, but also sustainability under intensive use. The new U701V from B Medical Systems, with variable-speed technology, delivers the perfect balance: uncompromised performance, reliability, and sustainability.
New developments under the current U.S. administration may be a challenge for the pharma/biotech industry: the Inflation Reduction Act, Orange Book Challenges, Most Favored Nation Policy, and the new Trump-Lutnick Patent Tax. And it will likely affect European pharma and biotech.
After two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success.
The global biologics industry is entering a new phase of maturity. As costs tighten and timelines accelerate, CDMOs must deliver uncompromised quality while driving efficiency. Rezon Bio, an EU-based biologics CDMO with state-of-the-art facilities and a client-centric approach, was established to meet biotech and pharmaceutical client needs with agility, pragmatism, and trust.
FairJourney Biologics (Porto, PT) has appointed Dr Werner Lanthaler, long-standing Evotec CEO, as Chief Executive Officer. Founder António Parada will focus on innovation strategy on the Supervisory Board.
Contract Research Organization Julius Clinical (NL) appointed Bassem Saleh as its new Chief Executive Officer. His predecessor, Martijn Wallert, will become an advisor to the Executive Board.
Tessellate Bio (Naarden, Netherlands; Stevenage, UK) appointed Dr Katie Chapman as Chief Scientific Officer (CSO) at the end of September. She succeeds Dr Jürgen Moll, who will be available to the company in an advisory capacity.
The Eppendorf BioFlo 120 bioprocess controller offers simplicity and ease of use, without sacrificing capability. No matter if you are in an academic, governmental or industrial research setting, the BioFlo 120 bioprocess controller is an attractive solution to meet your needs – all at an affordable price.
Stick, Tag, Destroy: The Science of PROTACs and MGDs – For a long time, traditional drug research focused on inhibitors that block the active sites of disease-related proteins. However, around 80% of these proteins remain “undruggable” because they lack clear binding sites.
Swedish AlzeCure Pharma AB recently appointed Cecilia Wadell as Head of Development. She joins also the management team.